<DOC>
	<DOCNO>NCT00400231</DOCNO>
	<brief_summary>Patients metabolic syndrome , insulin resistance , elevate triglyceride 150 mg/dl high randomize one four group : 1 ) placebo ; 2 ) metformin ; 3 ) fenofibrate ; 4 ) combine metformin fenofibrate period 12 week titration target dose . We interested effect therapy triglyceride level , HDL-C , insulin resistance , marker inflammation .</brief_summary>
	<brief_title>The Fenofibrate Metformin Atherogenic Dyslipidemia ( FAMA ) Study</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Subjects age 18 75 follow risk factor : 1 . Fasting triglyceride &gt; = 150 mg/dl ( le 800 mg/dl ) 2 . Glucose 140 199 mg/dl , 2 hour 75 gm oral glucose load , fast HOMA level upper quartile ( &gt; 2.68 ) , plasma triglyceride high density lipoprotein cholesterol concentration &gt; 3.0 And least one follow three : 1 . Central obesity ( waist size &gt; 40 inch men &gt; 35 inch woman ) 2 . A systolic blood Pressure &gt; 130 mmHg and/or diastolic blood pressure &gt; 85 mmHg and/or take antihypertensive medication . 3 . HDL &lt; 40 mg/dl men &lt; 50 mg/dl woman 1 . Blood pressure &gt; 180/95 mmHg ( subject may rescreened adequate blood pressure control obtain ) 2 . Women pregnant lactating , childbearing potential use acceptable method birth control . 3 . Chronic renal insufficiency ( serum creatinine &gt; 1.5 mg/dl men &gt; 1.4 mg/dl woman 4 . Any active liver disease abnormal LFTs ( &gt; 2x upper limit normal ) ( 12 ) 5 . Active infection , malignancy chronic inflammatory disorder 6 . Concomitant use niacin , bile acid sequestrant , ezetimibe . If deem safe patient 's primary physician principal investigator , patient may screen enrollment upon stop medication least 2 week . 7 . Subjects statins need less maximal dose ( e.g . &lt; 80 mg per day simvastatin atorvastatin ) . Subjects also need stable dose statin therapy least 1 month prior enrollment continue currently prescribe statin dose throughout study . If deem safe patient 's primary physician principal investigator , patient maximal statin therapy ( usually 80 mg/day ) may reduce dose statin therapy sub maximal dose ( usually 40 mg/day ) 4 week prior screen enrollment . 8 . History lactic acidosis ( 12 ) 9 . Expected need use intravenous radiographic contrast study 10 . More moderate alcohol use ( &gt; 14 drink per week ) 11 . Moderate severe leave ventricular dysfunction ( ejection fraction &lt; 45 % ) 12 . Decompensated heart failure decompensated lung disease result hypoxia reduce peripheral perfusion within past year regardless leave ventricular ejection fraction ( thus patient underlie heart disease , coronary artery disease , mild leave ventricular dysfunction ( ejection fraction &gt; 45 % ) , lung disease stable least one year eligible participate ) 13 . Creatinine kinase ( CK ) level â‰¥ 2.5 ULN history statininduced myopathy . Patients CK level 2.5 time upper limit normal may undergo repeat test two time exclude ( since vigorous physical activity often elevate CK level , would increase risk myopathy ) . 14 . Participation investigational drug study within 6 week prior screen visit 15 . Surgery within previous 30 day 16 . Concomitant use ketoconazole , itraconazole , cyclosporin A , erythromycin , Clarithromycin . 17 . Hemoglobin &lt; 10 mg/dl , active use coumadin , history bleed disorder , abnormal clotting time ( protime &gt; 14.6 second aPTT &gt; 37.0 ) 18 . Septic shock 19 . Acute coronary syndrome stroke within 3 month prior study 20 . Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>inflammation</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Elevated triglyceride</keyword>
	<keyword>without diabetes</keyword>
</DOC>